Headaches on a GLP-1: how common they were in the trials

Reviewed 18 sourcesPublished by PepVault

Headache hit 14% on Wegovy vs 10% on placebo, while tirzepatide's trials matched placebo. Every label and trial side by side, why it happens and what helps.

Man with short locs in a white tee meditates cross-legged on a park lawn
Last reviewed
Sources
18
Questions
7
Compounds
2

The short answer

Less common than most people expect, and barely above placebo. Wegovy's label counts headache in 14% of adults against 10% on placebo. The Zepbound, Mounjaro and Ozempic labels list no trial rate at all, and in Zepbound's main trial 7 to 8% had a headache against 7.3% on placebo. The likeliest triggers are eating and drinking less, so regular meals and fluids are the first fix.

Every number checked at its primary source · · 18 sources · How we research

Evidence: FDA prescribing information for Wegovy, Zepbound, Ozempic and Mounjaro (DailyMed, versions current on November 20, 2026); the posted results of seven placebo-controlled trials on ClinicalTrials.gov, all run by Novo Nordisk or Eli Lilly; a maker-funded pooled analysis of the STEP trials (2022); the International Headache Society's classification; one small randomised trial and one review in raised brain pressure; one Danish register study.

Man with short locs in a white tee meditates cross-legged on a park lawn

How common are headaches on Wegovy, Ozempic, Mounjaro and Zepbound?

Of the four US labels, only Wegovy's puts headache in its trial tables, and only a few points above placebo (a dummy injection given to the comparison group). The other three list headache only among the signs of low blood sugar, or among reports sent in after approval. Here is each label's own line, as of November 20, 2026:

Label and trialsHeadache on placeboHeadache on the drug
Wegovy 2.4 mg, adults, three weight trials up to 68 weeks10%14%1
Wegovy 7.2 mg, adults, two 72-week trials7%9%, against 8% on 2.4 mg1
Wegovy 2.4 mg, teens 12 to 17, 68 weeks16%17%1
Zepbound 5, 10 and 15 mg, adults, two 72-week trialsNot listedNot in the table of effects seen in 2% or more and more often than on placebo2
Ozempic 0.5 and 1 mg, type 2 diabetes trialsNot listedOnly among reports after approval, with no rate3
Mounjaro, type 2 diabetes trialsNot listedNot in the table of effects at 5% or more4

In the Wegovy pill's 64-week trial, the kinds and rates of common side effects were similar to the 2.4 mg injection's1. Every label warns that rates from different trials cannot be compared directly, so read each row against its own placebo12. In the teen trial the gap is one point: 16 in 100 teens on placebo had a headache too1.

In PepVault, a headache goes in the side-effect log under the compound you take, with its date, a severity from minimal to very severe and a note for what you ate, drank and slept. Log it in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

In PepVault, a headache goes in the side-effect log under the compound you take, with its date, a severity from minimal to very severe and a note for what you ate, drank and slept.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How many people got headaches in the STEP, SUSTAIN, SURMOUNT and SURPASS trials?

The trials' own results, posted on ClinicalTrials.gov, count every headache anyone reported during the trial, whatever its cause. That fills in the brands whose labels give no number. Each count below is the people with a headache out of everyone who got at least one dose:

Trial (drug, who)PlaceboDrug
STEP 1 (semaglutide 2.4 mg, weight loss, 75 weeks)12.2% (80 of 655)15.2% (198 of 1,306)5
STEP 2 (semaglutide, weight loss with type 2 diabetes, 75 weeks)5.0% (20 of 402)8.2% on 1 mg, 7.7% on 2.4 mg6
STEP 3 (semaglutide 2.4 mg with an intensive diet program, 75 weeks)9.8% (20 of 204)19.2% (78 of 407)7
SUSTAIN 1 (Ozempic 0.5 and 1 mg, type 2 diabetes, about 35 weeks)6.2% (8 of 129)11.7% on 0.5 mg, 6.9% on 1 mg8
SURMOUNT-1 (tirzepatide, weight loss, up to 193 weeks)7.3% (47 of 643)7.5% on 5 mg, 8.0% on 10 mg, 7.0% on 15 mg9
SURMOUNT-2 (tirzepatide, weight loss with type 2 diabetes, 76 weeks)2.9% (9 of 315)5.1% on 10 mg, 4.8% on 15 mg10
SURPASS-1 (Mounjaro, type 2 diabetes, up to 44 weeks)7.8% (9 of 115)4.1% on 5 mg, 3.3% on 10 mg, 4.1% on 15 mg11

The biggest gap is STEP 3, where both groups also spent their first two months on a low-calorie diet of bars, shakes and one meal a day; on top of that diet, 19 in 100 on semaglutide had a headache against about 10 on placebo7. That fits the likeliest trigger, eating far less, which the section on why it happens explains.

Is semaglutide or tirzepatide more likely to give you headaches?

Semaglutide, on these numbers. Across the STEP trials, people on Wegovy's dose had a headache about 3 to 9 points more often than placebo567. Tirzepatide's results sit right on placebo: in SURMOUNT-1, 7.0 to 8.0% against 7.3% across up to three years, and in SURPASS-1 fewer people on Mounjaro reported one than on placebo911. SURMOUNT-2 is the one tirzepatide trial with a gap, about 2 points10.

No trial put the two drugs head to head on headache, so this is a comparison of separate trials, each against its own placebo12. Our guide to semaglutide and tirzepatide side effects sets the stomach effects side by side the same way.

When do headaches start on a GLP-1, and do they pass?

No label and no trial record gives headache by week1259. The clue is in what drives most of them: eating less. Both labels raise the dose every four weeks, Wegovy from 0.25 mg up to 2.4 mg and Zepbound from 2.5 mg in 2.5 mg steps12. In the STEP trials, nausea, vomiting and diarrhea were mostly mild to moderate, passed, and came most often during or shortly after the dose climb12. No study has timed the headaches, but if most come from eating and drinking less, the first weeks and the days after each step-up are when to expect them, and they should ease as the stomach effects do.

A headache from fasting has a pattern that is easy to spot. The International Headache Society defines it as a dull, all-over headache, mild to moderate, that comes after at least eight hours without food and clearly improves after eating13. If you drank coffee every day and now drink much less, a caffeine-withdrawal headache can start within a day and clears within a week14.

Commonly reported: very little. On our tirzepatide and semaglutide reviews pages (checked November 19, 2026), 1 of 77 tirzepatide write-ups names headaches as an unwanted effect and 1 names fewer headaches; none of 41 semaglutide write-ups mentions them.

Why would a GLP-1 give you a headache?

Mostly through what it does to eating and drinking, not through a direct effect on the head. A GLP-1 slows the stomach and quiets hunger, so long gaps without food come easily, and the fasting headache follows13. Nausea, vomiting and diarrhoea drain fluid: all four labels say these can cause a loss of fluids, and that drinking fluids lowers the chance of it1234. Less food can also mean less coffee, and so a caffeine-withdrawal headache14.

With diabetes there is one more cause. All four labels list headache among the signs of low blood sugar, alongside shakiness, sweating, hunger and confusion1234. The risk sits mainly with insulin or a sulfonylurea (glipizide, glimepiride, glyburide: older diabetes pills)2. Our guide to low blood sugar on a GLP-1 has the rates and the steps for treating a low.

Can a GLP-1 make headaches better?

For some headaches, the early studies point that way. Idiopathic intracranial hypertension is raised fluid pressure around the brain with no known cause; it brings frequent headaches and can swell the optic nerve and blur sight16. In a randomised trial of 15 women with it (average BMI 38), a GLP-1 drug, exenatide, lowered the pressure by 5.7 cm of spinal fluid at 2.5 hours, against placebo, and the drop held at 24 hours and 12 weeks15. A 2025 review of four studies with 1,550 patients found about 3.6 fewer headache days a month at three months on GLP-1 drugs than on standard care16.

For migraine the signal is smaller. In Denmark, among 189,392 people who started semaglutide for weight loss, use of triptans (migraine tablets) was 7% lower after a year than the earlier trend predicted; the fall was in women, not men, and largest in people aged 18 to 35 and in those who had used migraine-prevention medicine17. The authors call the fall modest and gradual, and it came mostly from people already using triptans taking fewer. It is a register study, so it shows a link, not proof; two of its authors work for Novo Nordisk, semaglutide's maker17.

What helps a headache on a GLP-1?

  1. Eat something. A fasting headache improves after food, so a small meal or snack is the first test13.
  2. Drink. The labels' own advice is fluids, most of all on a day of nausea, vomiting or diarrhoea12.
  3. If you use insulin or a sulfonylurea, check your blood sugar, since headache is one of the signs of a low; our low blood sugar guide has the steps2.
  4. Keep your coffee steady. In someone used to more than 200 mg of caffeine a day, a withdrawal headache starts within a day of the last cup, eases within an hour of 100 mg of caffeine, and clears within a week without it14.
  5. Space meals through the day; the fasting headache is defined after eight hours or more without food, so shorter gaps keep you clear of it13.
  6. Ask your pharmacist or prescriber which pain reliever suits you; vomiting or diarrhoea that does not stop is theirs to hear about too12.

PepVault's food log shows what you ate and when, so a headache in the side-effect log can be read against the day's meals. Track your food in PepVault

When to get help A sudden, explosive or worst-ever headache, or one with slurred speech, a change in vision, weakness, confusion, fever with a stiff neck, or that keeps getting worse over a day, needs emergency care right away18.

Track it in the app

Sources

  1. WEGOVY (semaglutide) injection and tablets prescribing information, Novo Nordisk, DailyMed (SPL version 19), June 30, 2026 dailymed.nlm.nih.gov
  2. ZEPBOUND (tirzepatide) injection prescribing information, Eli Lilly, DailyMed (SPL version 40), September 2, 2026 dailymed.nlm.nih.gov
  3. OZEMPIC (semaglutide) injection prescribing information, Novo Nordisk, DailyMed (SPL version 20), June 10, 2026 dailymed.nlm.nih.gov
  4. MOUNJARO (tirzepatide) injection prescribing information, Eli Lilly, DailyMed (SPL version 40), September 2, 2026 dailymed.nlm.nih.gov
  5. STEP 1: semaglutide 2.4 mg in overweight or obesity (NCT03548935), Novo Nordisk. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  6. STEP 2: semaglutide in type 2 diabetes with overweight or obesity (NCT03552757), Novo Nordisk. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  7. STEP 3: semaglutide with an intensive lifestyle program (NCT03611582), Novo Nordisk. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  8. SUSTAIN 1: once-weekly semaglutide versus placebo in drug-naive type 2 diabetes (NCT02054897), Novo Nordisk. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  9. SURMOUNT-1: tirzepatide in obesity or overweight (NCT04184622), Eli Lilly. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  10. SURMOUNT-2: tirzepatide in type 2 diabetes with obesity or overweight (NCT04657003), Eli Lilly. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  11. SURPASS-1: tirzepatide in type 2 diabetes not controlled with diet and exercise (NCT03954834), Eli Lilly. Posted results, adverse events. ClinicalTrials.gov. clinicaltrials.gov
  12. Wharton S, Calanna S, Davies M, Dicker D, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. PubMed 34514682
  13. International Headache Society. ICHD-3, 10.5 Headache attributed to fasting. ichd-3.org
  14. International Headache Society. ICHD-3, 8.3.1 Caffeine-withdrawal headache. ichd-3.org
  15. Mitchell JL, Lyons HS, Walker JK, Yiangou A, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830. PubMed 36907221
  16. Stefanou MI, Chatziralli I, Lambadiari V, Mengel A, et al. Efficacy and safety of GLP-1 and dual GIP/GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis. Eur J Neurol. 2025;32(9):e70358. PubMed 40937960
  17. Roland N, Sonne H, Pellesi L, Bramming M, et al. Impact of semaglutide introduction on the use of triptans: an interrupted-time series. J Headache Pain. 2026;27(1):199. PubMed 42557547
  18. MedlinePlus Medical Encyclopedia. Headache. Review date October 27, 2025. medlineplus.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo